+

WO2003038063A3 - Human secreted proteins - Google Patents

Human secreted proteins Download PDF

Info

Publication number
WO2003038063A3
WO2003038063A3 PCT/US2002/008277 US0208277W WO03038063A3 WO 2003038063 A3 WO2003038063 A3 WO 2003038063A3 US 0208277 W US0208277 W US 0208277W WO 03038063 A3 WO03038063 A3 WO 03038063A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
present
human secreted
polynucleotides
encompassed
Prior art date
Application number
PCT/US2002/008277
Other languages
French (fr)
Other versions
WO2003038063A2 (en
Inventor
Craig A Rosen
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to AU2002363296A priority Critical patent/AU2002363296A1/en
Priority to CA002441755A priority patent/CA2441755A1/en
Priority to EP02799146A priority patent/EP1390390A4/en
Publication of WO2003038063A2 publication Critical patent/WO2003038063A2/en
Publication of WO2003038063A3 publication Critical patent/WO2003038063A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating hematopoietic and hematologic diseases, disorders, and/or conditions related thereto. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
PCT/US2002/008277 2001-03-21 2002-03-19 Human secreted proteins WO2003038063A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002363296A AU2002363296A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
CA002441755A CA2441755A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02799146A EP1390390A4 (en) 2001-03-21 2002-03-19 Human secreted proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US60/277,340 2001-03-21
US30617101P 2001-07-19 2001-07-19
US60/306,171 2001-07-19
US33128701P 2001-11-13 2001-11-13
US60/331,287 2001-11-13

Publications (2)

Publication Number Publication Date
WO2003038063A2 WO2003038063A2 (en) 2003-05-08
WO2003038063A3 true WO2003038063A3 (en) 2003-12-11

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
PCT/US2002/009785 WO2002095010A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008276 WO2002076488A1 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008124 WO2003004622A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008279 WO2002090526A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008123 WO2002102993A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008278 WO2002102994A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008277 WO2003038063A2 (en) 2001-03-21 2002-03-19 Human secreted proteins

Family Applications Before (6)

Application Number Title Priority Date Filing Date
PCT/US2002/009785 WO2002095010A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008276 WO2002076488A1 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008124 WO2003004622A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008279 WO2002090526A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008123 WO2002102993A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008278 WO2002102994A2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Country Status (4)

Country Link
EP (7) EP1381622A2 (en)
AU (6) AU2002363296A1 (en)
CA (7) CA2441832A1 (en)
WO (7) WO2002095010A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
JP2002513295A (en) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 123 human secreted proteins
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6329503B1 (en) 1998-06-01 2001-12-11 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
CN1387538A (en) 1999-01-15 2002-12-25 比奥根公司 Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004528823A (en) 2000-10-31 2004-09-24 ディアデクサス インコーポレーテッド Compositions and methods for colon-specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030100497A1 (en) 2001-06-20 2003-05-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2532757T3 (en) 2001-09-06 2015-03-31 Agensys, Inc. Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
CA2463596A1 (en) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Method of screening cell death inhibitor
ES2444121T3 (en) 2002-04-09 2014-02-24 Biogen Idec Ma Inc. Procedures for treating conditions related to TWEAK
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK1842920T4 (en) 2003-09-23 2017-08-21 Univ North Carolina Chapel Hill Cells that co-express vitamin K reductase and vitamin K-dependent protein, as well as their use to improve the productivity of vitamin K-dependent protein
AU2004283246B2 (en) * 2003-10-14 2009-07-23 Baxalta GmbH Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
US20070269421A1 (en) * 2004-02-03 2007-11-22 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Plasma Glutamate Carboxypeptidase (Pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EA014870B1 (en) 2004-04-22 2011-02-28 Эдженсис, Инк. Antibodies that bind to steap-1 proteins
PT1794174E (en) * 2004-09-01 2012-08-16 Dynavax Tech Corp Methods and compositions for inhibition of innate immune responses and autoimmunity
EP1799849A4 (en) * 2004-09-07 2008-07-09 Telethon Inst For Child Health AGENTS FOR THE TREATMENT OR PREVENTION OF ALLERGIC DISEASES
WO2006026808A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Method of diagnosing and/or predicting the development of an allergic disorder
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
AU2006218216B2 (en) 2005-02-28 2011-01-20 Baxalta GmbH Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependent protein expression
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
GB2445882B (en) * 2005-09-01 2011-02-23 Florey Howard Inst Prophylactic and therapeutic agents and compositions and uses therefor and methods for determining the presence or severity of neuronal damage
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
ES2387924T3 (en) 2006-10-27 2012-10-04 Genentech, Inc. Antibodies and immunoconjugates and uses for them
WO2008063382A2 (en) 2006-11-07 2008-05-29 Merck & Co., Inc. Antagonists of pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2008118386A2 (en) 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2361980B1 (en) 2007-10-26 2016-12-07 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
EP2215268B1 (en) * 2007-11-30 2018-08-29 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
US8877900B2 (en) 2009-10-30 2014-11-04 Merck Sharp & Dohme Corp. AX132 PCSK9 antagonists
AU2010313381A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
MX338980B (en) 2010-06-16 2016-05-06 Dynavax Tech Corp Methods of treatment using tlr7 and/or tlr9 inhibitors.
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 Substituted nucleotide analog
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
AU2017281830B2 (en) 2016-06-20 2023-04-06 Kymab Limited Anti-PD-L1 antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017382323B2 (en) 2016-12-23 2024-06-13 President And Fellows Of Harvard College Gene editing of PCSK9
PE20200010A1 (en) 2017-04-03 2020-01-06 Hoffmann La Roche ANTIBODIES THAT JOIN STEAP-1
WO2018237212A1 (en) 2017-06-22 2018-12-27 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited organic coating
EP3642383B1 (en) * 2017-06-22 2022-12-21 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating
CA3179862A1 (en) 2020-04-09 2021-10-14 Verve Therapeutics, Inc. Base editing of angptl3 and methods of using same for treatment of disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (en) * 1996-02-02 1999-12-15 나까니시 히로유끼 A pharmaceutical preparation containing a human growth hormone
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins
JP2002520050A (en) * 1998-07-15 2002-07-09 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 71 human secreted proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides
US6174994B1 (en) * 1997-05-30 2001-01-16 Smithkline Beecham Corporation 7TM receptor (H2CAA71)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1390390A4 *

Also Published As

Publication number Publication date
EP1379264A4 (en) 2009-07-08
CA2441417A1 (en) 2002-11-14
CA2441755A1 (en) 2003-05-08
CA2441832A1 (en) 2002-12-27
WO2002095010A3 (en) 2004-02-12
AU2002332391A1 (en) 2003-01-02
EP1379132A2 (en) 2004-01-14
EP1379132A4 (en) 2009-07-01
AU2002324424A1 (en) 2002-12-03
WO2002095010A2 (en) 2002-11-28
EP1404702A4 (en) 2009-07-08
EP1404702A2 (en) 2004-04-07
EP1390390A4 (en) 2009-07-08
AU2002363296A1 (en) 2003-05-12
WO2002076488A1 (en) 2002-10-03
WO2003038063A2 (en) 2003-05-08
EP1423134A2 (en) 2004-06-02
CA2441416A1 (en) 2003-01-16
EP1414845A2 (en) 2004-05-06
EP1381622A2 (en) 2004-01-21
WO2002102993A2 (en) 2002-12-27
EP1414845A4 (en) 2009-07-08
AU2002326293A1 (en) 2003-01-02
CA2441397A1 (en) 2002-10-03
WO2002102994A3 (en) 2003-07-24
WO2003004622A3 (en) 2004-02-19
WO2002102993A3 (en) 2004-03-25
WO2002090526A2 (en) 2002-11-14
AU2002320013A1 (en) 2002-11-18
EP1390390A2 (en) 2004-02-25
EP1379264A1 (en) 2004-01-14
WO2002102994A2 (en) 2002-12-27
AU2002354719A1 (en) 2003-01-21
WO2003004622A2 (en) 2003-01-16
WO2002090526A3 (en) 2003-10-30
CA2441840A1 (en) 2002-11-28
CA2441702A1 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
WO2003038063A3 (en) Human secreted proteins
WO2002092787A3 (en) Human secreted proteins
WO2001055364A8 (en) Nucleic acids, proteins, and antibodies
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO2001055306A3 (en) Nucleic acids, proteins, and antibodies
WO2004042000A3 (en) 157 human secreted proteins
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO2001055440A8 (en) Nucleic acids, proteins, and antibodies
WO2002072763A3 (en) Nucleic acids, proteins, and antibodies
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
WO2001055305A3 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2441755

Country of ref document: CA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002799146

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002799146

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载